Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics

The success of the messenger RNA-based COVID-19 vaccines of Moderna and Pfizer/BioNTech marks the beginning of a new chapter in modern medicine. However, the rapid rise of mRNA therapeutics has resulted in a regulatory framework that is somewhat lagging. The current guidelines either do not apply, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Vervaeke, P., Borgos, S.E., Sanders, N.N., Combes, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957368/
https://www.ncbi.nlm.nih.gov/pubmed/35351470
http://dx.doi.org/10.1016/j.addr.2022.114236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957368/
https://www.ncbi.nlm.nih.gov/pubmed/35351470
http://dx.doi.org/10.1016/j.addr.2022.114236

Ejemplares similares